Premium
A meta‐analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes
Author(s) -
Monami M.,
Dicembrini I.,
Kundisova L.,
Zani S.,
Nreu B.,
Mannucci E.
Publication year - 2014
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12287
Subject(s) - medicine , incidence (geometry) , placebo , diabetes mellitus , type 2 diabetes , odds ratio , randomized controlled trial , relative risk , cumulative incidence , body mass index , confidence interval , endocrinology , cohort , physics , alternative medicine , pathology , optics
Aim To assess hypoglycaemic risk with sulphonylureas in comparison with other drugs in randomized controlled trials. Methods Randomized trials with a duration ≥24 weeks, enrolling patients with type 2 diabetes, comparing sulphonylureas with placebo or active drugs different from other sulphonylureas. The principal outcome was the effect of sulphonylureas on the incidence of any or severe hypoglycaemia. Cumulative incidence of hypoglycaemia was estimated combining sulphonylurea groups of different trials with a random effect model and used for meta‐regression analyses. Results The incidence of severe hypoglycaemia in patients treated with sulphonylureas was 1.2 [1.0–1.6]%. The overall risk of severe hypoglycaemia was increased more than threefold with sulphonylureas than with comparators. The proportion of patients with at least one hypoglycaemia while on sulphonylureas was 17.4 [14.5–20.8]%. The overall risk (Mantel–Haenszel Odds Ratio) of any hypoglycaemia with sulphonylureas versus comparators was 3.69 [3.47–3.93] (p < 0.001). Meta‐regression analysis suggested that the incidence of any hypoglycaemia was higher in trials enrolling patients with higher body mass index ( BMI ) and lower haemoglobin A1c ( HbA1c ). Conclusions In conclusion, hypoglycaemia, including severe hypoglycaemia, is frequent in patients treated with sulphonylureas, particularly when baseline HbA1c levels are lower and BMI levels higher. Further studies are needed to characterize predictors for the identification of patients at higher risk.